The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes. Issue 4 (14th February 2022)

• Record Type: Journal Article
• Authors: Björn, Niclas; Jakobsen, Ingrid; Udagawa, Chihiro; Brandén, Eva; Koyi, Hirsh; Lewensohn, Rolf; De Petris, Luigi; Zembutsu, Hitoshi; Gréen, Henrik
• Is Part Of: Basic & clinical pharmacology & toxicology. Volume 130:Issue 4(2022)
• Page Start: 513
• Page End: 521
• Publication Date: 2022-02-14
• Subjects: adverse drug reactions -- carboplatin -- gemcitabine -- myelosuppression -- non‐small cell lung cancer; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology, Clinical -- Periodicals; Computer network resources; Electronic journals; 615.1
• DOI: 10.1111/bcpt.13712
• Languages: English
• ISSNs: 1742-7835

Abstract

Abstract: Gemcitabine/carboplatin‐induced myelosuppressive adverse drug reactions (ADRs) are clinical problems leading to patient suffering and dose alterations. There is a need for personalised medicine to improve treatment effects and patients' well‐being. We tested four genetic variants, rs11141915, rs1901440, rs12046844 and rs11719165, previously suggested as potential biomarkers for gemcitabine‐induced leukopenia/neutropenia in Japanese patients, in 213 Swedish gemcitabine/carboplatin‐treated non‐small cell lung cancer (NSCLC) patients. DNA was genotyped using TaqMan probes and real‐time PCR. The relationships between the risk alleles and low toxicity (non‐ADR: Common Terminology Criteria for Adverse Events [CTCAE] grades 0) or high toxicity (ADR: CTCAE grades 3–4) of platelets, leukocytes and neutrophils were evaluated using Fisher's exact test. The risk alleles did not correlate with myelosuppression, and the strongest borderline significance (not withstanding adjustment for multiple testing) was for rs1901440 (neutropenia, p = 0.043) and rs11719165 (leukopenia, p = 0.049) where the risk alleles trended towards lower toxicity, contrasting with previous study findings. Risk alleles and higher risk scores were more common among our patients. We conclude that the genetic variants do not apply to Swedish patients treated with gemcitabine/carboplatin. However, they can still be important in other populations and cohorts, especially in a gemcitabine monotherapy setting, where the causal genetic variation might influence myelosuppressive ADRs.